Please login to the form below

Not currently logged in
Email:
Password:

Drug industry forms disaster response group

Rx Response, a programme designed to support the delivery of medicines during a disaster or severe public health emergency, was launched today by healthcare organisations involved in the manufacture, distribution and dispensing of pharmaceutical products

Rx Response, a programme designed to support the delivery of medicines during a disaster or severe public health emergency, was launched today by healthcare organisations involved in the manufacture, distribution and dispensing of pharmaceutical products.

Billy Tauzin, a former US representative from Louisiana, and now president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) said: "During a disaster, it is vital that systems are in place to assist with the continued delivery of medicines to hospitals, healthcare providers and patients in need."

In the past, when the pharmaceutical supply chain was disrupted, there was no single forum for suppliers to convene and share information. Rx Response will expedite information sharing among its partners, community volunteer relief organisations, as well as local, state and federal agencies responding to major disasters.

The partnership includes the American Hospital Association, American Red Cross, Biotechnology Industry Organisation, Healthcare Distribution Management Association, National Association of Chain Drug Stores, National Community Pharmacists Association and PhRMA.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics